Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma

Completed · Phase 2

Conditions studied: Malignant Mesothelioma

In brief

RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with previously treated malignant mesothelioma.

Key facts

Study ID
NCT00509041
Run by
Alliance for Clinical Trials in Oncology
People needed
46
Starts
2007-08-01
Expected to finish
2012-12-01
Last updated by the study team
2016-08-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.